WESTMONT, Ill., Jan. 7 /PRNewswire/ -- PKB Animal Health, Inc., makers of Zymox® Otic and Zymox® Topical Spray announce scientific research demonstrating effectiveness of the enzyme-based products against Methicillin-resistant Staphylococcus aureus, MRSA.
Zymox® adds a much needed level of confidence in the ability to manage stubborn infections of the ears and skin of dogs and cats, including antibiotic resistant microorganisms such as MRSA. This discovery has timely benefits as there has been growing concern in the veterinary community regarding treatment and prevention of MRSA and the potential for pets to spread this bacteria to people.
According to published research, both Zymox® Otic for ear infections and Zymox® Topical Spray for skin infections, wounds and cuts have been shown to eradicate MRSA in as little as 30 seconds upon contact. Gentle on skin, yet effective on microbes, Zymox® utilizes the patented LP3 Enzyme System which is non-toxic and formulated without antibiotics, chlorhexidine, harsh detergents or chemicals. Zymox® requires no pre-cleaning and is applied only once a day.
PKB Animal Health, Inc. has been dedicated for over 10 years to providing antimicrobial enzyme-based products for topical use which are safe, non-toxic and proven to be effective antibiotic alternatives. PKB Animal Health also offers an enzyme-based product line for pet oral care as well.
To view the research, use the following web links
SOURCE PKB Animal Health, Inc.